Literature DB >> 25625029

(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.

Katherine A Zukotynski1, Chun K Kim2, Victor H Gerbaudo3, Jon Hainer3, Mary-Ellen Taplin4, Philip Kantoff4, Annick D Van den Abbeele2, Steven Seltzer2, Christopher J Sweeney4.   

Abstract

To evaluate (18)F-labeled-fluorodeoxyglucose ((18)F-FDG-) and (18)F-labeled-sodium fluoride ((18)F-NaF-) positron emission tomography/computed tomography (PET/CT) as biomarkers in metastatic castrate-resistant prostate cancer (mCRPC). Nine men (53-75 years) in a phase 1 trial of abiraterone and cabozantinib had (18)F-FDG-PET/CT, (18)F-NaF-PET/CT and standard imaging ((99m)Tc-labeled-methylene-diphosphonate ((99m)Tc-MDP) bone scan and abdominal/pelvic CT) at baseline and after 8 weeks of therapy. Baseline disease was classified as widespread (18)F-FDG-avid, oligometastatic (18)F-FDG-avid (1 site), or non-(18)F-FDG-avid. Metabolic response was classified using European Organisation for Research and Treatment of Cancer (EORTC) criteria. Treatment response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Prostate Cancer Working Group 2 (PCWG2) guidelines and days on trial (DOT) were recorded. All men were followed for 1 year or until progression. Four men had (18)F-FDG-avid disease: two with widespread (DOT 53 and 76) and two with oligometastatic disease (DOT 231 and still on trial after 742+ days). Five men had non-(18)F-FDG-avid disease; three remained stable or improved (2 still on trial while one discontinued for non-oncologic reasons; DOT 225-563+), and 2 progressed (DOT 285 and 532). Despite the small sample size, Kaplan-Meier analysis showed a significant difference in progression free survival (PFS) between men with widespread (18)F-FDG-avid, oligometastatic (18)F-FDG-avid and non-(18)F-FDG-avid disease (p < 0.01). All men had (18)F-NaF-avid disease. Neither (18)F-NaF-avid disease extent nor intensity was predictive of treatment response. (18)F-FDG-PET/CT may be superior to (18)F-NaF-PET/CT and standard imaging in men with mCRPC on abiraterone and cabozantinib. (18)F-FDG-PET/CT may have potential to stratify men into 3 groups (widespread vs. oligometastatic (18)F-FDG-avid vs. non-(18)F-FDG-avid mCRPC) to tailor therapy. Further evaluation is warranted.

Entities:  

Keywords:  FDG; NaF; PET/CT; bone scan; prostate cancer

Year:  2014        PMID： 25625029      PMCID： PMC4299771     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  40 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.

Authors:  Ryogo Minamimoto; Hiroji Uemura; Futoshi Sano; Hideyuki Terao; Yoji Nagashima; Shoji Yamanaka; Kazuya Shizukuishi; Ukihide Tateishi; Yoshinobu Kubota; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2010-10-08       Impact factor: 2.668

3.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

Authors:  U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  1997-01       Impact factor: 5.209

4.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

5.  Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Lucy Hanna; Fenghai Duan; Anthony F Shields; R Edward Coleman
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

8.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

9.  Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Authors:  John M Fitzpatrick; Joaquim Bellmunt; Karim Fizazi; Axel Heidenreich; Cora N Sternberg; Bertrand Tombal; Antonio Alcaraz; Amit Bahl; Sergio Bracarda; Giuseppe Di Lorenzo; Eleni Efstathiou; Stephen P Finn; Sophie Fosså; Silke Gillessen; Pirkko-Liisa Kellokumpu-Lehtinen; Frédéric E Lecouvet; Stephane Oudard; Theo M de Reijke; Craig N Robson; Maria De Santis; Bostjan Seruga; Ronald de Wit
Journal:  Eur J Cancer       Date:  2014-04-03       Impact factor: 9.162

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321
View more
  8 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

Review 2.  18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

3.  miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.

Authors:  Dibash K Das; Michelle Naidoo; Adeodat Ilboudo; Jong Y Park; Thahmina Ali; Konstantinos Krampis; Brian D Robinson; Joseph R Osborne; Olorunseun O Ogunwobi
Journal:  Exp Cell Res       Date:  2016-09-29       Impact factor: 3.905

4.  Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Authors:  Pietro Ghedini; I Bossert; L Zanoni; F Ceci; T Graziani; P Castellucci; V Ambrosini; F Massari; E Nobili; B Melotti; A Musto; S Zoboli; L Antunovic; M Kirienko; A Chiti; C Mosconi; A Ardizzoni; R Golfieri; S Fanti; C Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-30       Impact factor: 9.236

5.  Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

Authors:  Jacob Farnebo; Agnes Wadelius; Per Sandström; Sten Nilsson; Hans Jacobsson; Lennart Blomqvist; Anders Ullén
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

6.  Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer.

Authors:  Ismet Sarikaya; Abdelhamid Elgazzar; Ali Sarikaya; Mahmoud Alfeeli
Journal:  World J Nucl Med       Date:  2018 Jul-Sep

7.  A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Authors:  Stephanie A Harmon; Esther Mena; Joanna H Shih; Stephen Adler; Yolanda McKinney; Ethan Bergvall; Sherif Mehralivand; Adam G Sowalsky; Anna Couvillon; Ravi A Madan; James L Gulley; Janet Eary; Ronnie C Mease; Martin G Pomper; William L Dahut; Baris Turkbey; Liza Lindenberg; Peter L Choyke
Journal:  Oncotarget       Date:  2018-12-28

8.  Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.

Authors:  Erik M Velez; Bhushan Desai; Lingyun Ji; David I Quinn; Patrick M Colletti; Hossein Jadvar
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.